Gilead Sciences, Inc. and Merck , known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results